A new strategy to enhance the activity of proteasome inhibitors (PIs), which are standard-of-care agents in the treatment of multiple myeloma (MM), was recently reported. The study introduces a new drug candidate that overcomes PI resistance in cultured cells and extends survival in mouse models of MM.
from Top Health News -- ScienceDaily https://ift.tt/2z7xwvG
No comments:
Post a Comment